Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReFacto AF in Hemophilia A Surgery
NCT00243659Phase 3Completed
- Sponsor
- Pfizer
- Start
- Apr 2006
- Primary completion
- Jun 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, open-label trial of moroctocog alfa in hemophilia A (2 arms), sponsored by Pfizer. Primary endpoint: Number of Patients Who Achieved Hemostatic Efficacy After Surgery at 6 weeks. Started Apr 2006; status: completed.
02
Drugs
moroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00243659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00243659.